News

Pharmabiz2h
ViiV & MPP extend voluntary licensing long-acting injectable HIV treatment, Indian pharma to benefit
ViiV & MPP extend voluntary licensing long-acting injectable HIV treatment, Indian pharma to benefit: Our Bureau, Bengaluru Tuesday, July 15, 2025, 12:45 Hrs [IST] ViiV Healthcare ...
LiveLaw2h
S.3(k) Patents Act | Delhi High Court Declines Patent To US-Entity For System To Locate Users Sharing 'Sensitive Content' On P2P Networks
The Delhi High Court has declined a plea moved by US-based Kroll Information Assurance, seeking to patent 'System to locate ...
Aurobindo Pharma To Make HIV Long-Acting Injection, Supply To 133 Low & Middle-Income Countries
New Delhi: Aurobindo Pharma on Tuesday said it will manufacture and supply the long-acting injectable HIV treatment ...
AllAfrica on MSN2h
Momentum Builds For Long-Acting HIV Solutions As IAS 2025 Spotlights Scientific Progress, Funding Challenges And Leaders' Calls To Action
New WHO guidelines endorse long-acting injectable lenacapavir for HIV prevention, Medicines Patent Pool expands licence for long-acting injectable cabotegravir for treatment, and Merck’s once-monthly ...
Rediff Money2h
Aurobindo to Produce Long-Acting HIV Drug
Aurobindo Pharma will manufacture & supply long-acting injectable HIV treatment cabotegravir across 133 countries, including ...
Aurobindo Pharma to manufacture long-acting HIV treatment for global markets
Aurobindo Pharma to manufacture and supply long-acting injectable HIV treatment in 133 countries, offering alternative to ...
Ericsson swings to profit in Q2 as licensing, cost cuts boost margins
Investing.com -- Ericsson (ST: ERICb) on Tuesday reported a net profit of SEK 4.6 billion in the second quarter of 2025, reversing a SEK 11 billion loss in the same period last year. The turnaround ...
Sun Pharma launches alopecia drug Leqselvi in US after settling patent dispute
Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval ...
Momentum Builds For Long-Acting HIV Solutions As IAS 2025 Spotlights Scientific Progress, Funding Challenges
IAS 2025, the 13th IAS Conference on HIV Science, opened today with a call to accelerate access to long-acting HIV prevention and treatment innovations amid growing global funding challenges. Four ...